Jing Medicine (和径医药) has submitted the IND application for HJ-002-03, an EGFR-PROTAC, intended for patients with non-small cell lung cancer in China. HJ-002 is the first PROTAC in the IND stage developed by Jing Medicine.
 |
| https://doi.org/10.1016/j.ejmech.2022.114533 |
In 2022, Jing Medicine received IND approval for HJM-353, an EED inhibitor, in both China and the United States, however, no clinical study has been initiated as of yet.
In 2021, Jing Medicine filed a patent (WO2022268229) claiming the PROTACs targeting EGFR, ALK, and ROS1. These CRBN-based PROTACs, designed with Brigatinib analogs that target ALK and EGFR kinases, may offer a potential new approach for treating lung cancer by inducing targeted protein degradation.
| Brigatinib and Embodiments in the Patent |
E95 and E123 demonstrated potent degradation activity, with DC50 values around single-digit nM and achieving over 90% degradation (Dmax) for EGFR-DTC (Del19/T790M/C797S), EGFR-LTC (EGFR L858R/T790M/C797S), and EGFR-DC (EGFR Del19/C797S).
| DC50 and Dmax |
In 2018, Jing Medicine secured a worldwide licensing agreement with ShanghaiTech University for 6 PROTAC degrader drug candidates, with a total package exceeding $100 million.
-------------------------------------
In May 2023, Betta Pharmaceuticals licensed the development and commercialization rights of CFT8919, an EGFR-targeting PROTAC, in Greater China from C4 Therapeutics for an upfront payment of $10 million and a $25 million equity investment.C4 Therapeutics confirmed that Betta will initiate the Phase 1 clinical trial for CFT8919 in China, supporting future global studies of the drug.
In March 2023, Haisco received Investigational New Drug (IND) approval for HSK40118 in patients with advanced non-small cell lung cancer (NSCLC). The clinical trial (NCT06050980) was initiated in China the same month, with an estimated enrollment of around 220 patients.
Comments